Address Barriers to Treating Opioid Use Disorder During COVID-19

You play a key role in helping patients with opioid use disorder during COVID-19...to address barriers to care, isolation, and stress.

Make every effort to ensure patients have access to meds for opioid use disorder (OUD) to avoid disruptions in care.

Continue to expect many patients to use a buprenorphine/naloxone combo for OUD...at a usual buprenorphine dose of 12 to 16 mg/day for sublingual tabs, up to 24 mg/day.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote